Haleon Stock - Redburn downgrade and July earnings date in view
17.06.2026 - 16:08:45 | ad-hoc-news.de
Edited by ad hoc news Operations & Strategy Desk. Verified prior to publication on 06/17/2026, 16:07 CET. Details in the imprint.
Haleon (GB00BMX86B70) drew attention this week after Rothschild & Co Redburn cut its rating and price target, while the market is already looking toward the half-year earnings date at the end of July. A detailed press summary reported the downgrade alongside a modest share price reaction in London.
All news and key figures on Haleon stock
Background articles, regulatory filings and price data provide a broader context for Haleon ahead of its upcoming earnings update.
Redburn turns more cautious
A detailed market commentary states that Haleon shares slipped toward the lower ranks of the FTSE 100 after Rothschild & Co Redburn downgraded the stock to Neutral and cut its price target, citing concerns over the group’s sales growth trajectory.
According to that report, Haleon shares were recently trading around 332p in London, down just under 1% on the day of the call, while the FTSE 100 itself edged higher, underlining the stock’s relative underperformance at that moment.
Analyst consensus and July date
The same commentary highlights that despite Redburn’s move, the broader analyst community remains constructive, with around 18 ratings described as Outperform and an average price target of roughly GBP 4.15, implying upside from recent levels.
Haleon is also reported to be maintaining its organic revenue growth ambition of 3% to 5% for 2026 and continues to target high-single-digit adjusted operating profit growth at constant currency, underscoring management’s medium-term confidence.
Operational update and earnings focus
Looking ahead, the same press summary notes that Haleon plans to publish its half-year 2026 results on 07/30/2026, setting a clear near-term catalyst for investors watching how the business navigates consumer demand and input-cost dynamics.
The group positions itself as a focused consumer health company with well-known brands in oral care, pain relief and respiratory categories, and it continues to emphasize everyday health as its core strategic theme across markets worldwide.
The product behind the stock
Haleon generates most of its revenue from consumer health brands in oral health, pain relief and over-the-counter medicines, including widely recognized products such as Sensodyne toothpaste, which sits at the center of its oral care portfolio.
Where the stock trades today
The shares of Haleon (GB00BMX86B70) trade on the London Stock Exchange at about 332.00p as of 06/17/2026, 16:07 CET.
Key facts on Haleon stock
- Company: Haleon plc
- ISIN: GB00BMX86B70
- WKN: A3DTL7
- Ticker: HLN
- Venue: London Stock Exchange
- Price (as of 06/17/2026, 16:07 CET): 332.00p GBP
- Market cap: $40.12 billion USD (as of 06/2026)
- Sector / Industry: Health Care - Consumer Health Products
- Index membership: FTSE 100
- Next earnings date: 07/30/2026
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
